Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 3
1989 7
1990 2
1992 3
1993 3
1994 2
1995 4
1996 5
1997 9
1998 2
1999 4
2000 2
2001 1
2002 9
2003 2
2004 7
2005 7
2006 9
2007 6
2008 11
2009 13
2010 21
2011 16
2012 15
2013 12
2014 15
2015 16
2016 15
2017 11
2018 12
2019 13
2020 21
2021 22
2022 12
Text availability
Article attribute
Article type
Publication date

Search Results

267 results
Results by year
Filters applied: . Clear all
Page 1
Hepatitis C virus-related cryoglobulinemic vasculitis.
Mazzaro C, Mauro E, Ermacora A, Doretto P, Fumagalli S, Tonizzo M, Toffolutti F, Gattei V. Mazzaro C, et al. Among authors: gattei v. Minerva Med. 2021 Apr;112(2):175-187. doi: 10.23736/S0026-4806.20.07120-7. Epub 2020 Nov 16. Minerva Med. 2021. PMID: 33198444 Review.
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Mariotti B, Iannella E, Maurillo L, Venditti A, Gattei V, de Fabritiis P, Cantonetti M, Amadori S. Del Poeta G, et al. Among authors: gattei v. Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954. Drugs Today (Barc). 2016. PMID: 27252989 Review.
TLR9 signaling defines distinct prognostic subsets in CLL.
Efremov DG, Bomben R, Gobessi S, Gattei V. Efremov DG, et al. Among authors: gattei v. Front Biosci (Landmark Ed). 2013 Jan 1;18(1):371-86. doi: 10.2741/4108. Front Biosci (Landmark Ed). 2013. PMID: 23276930 Free article. Review.
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vigna E, Martino EA, Cassin R, D Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Monti P, Menichini P, Olivieri J, Cutrona G, Rossi D, Cuneo A, Di Raimondo F, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Morabito F, et al. Among authors: gattei v. Am J Hematol. 2021 Aug 1;96(8):E269-E272. doi: 10.1002/ajh.26201. Epub 2021 May 3. Am J Hematol. 2021. PMID: 33878220 Free article. No abstract available.
Epigenetic immunomodulation of hematopoietic malignancies.
Gattei V, Fonsatti E, Sigalotti L, Degan M, Di Giacomo AM, Altomonte M, Calabrò L, Maio M. Gattei V, et al. Semin Oncol. 2005 Oct;32(5):503-10. doi: 10.1053/j.seminoncol.2005.07.006. Semin Oncol. 2005. PMID: 16210091 Review.
COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.
Del Poeta G, Bomben R, Polesel J, Rossi FM, Pozzo F, Zaina E, Cattarossi I, Varaschin P, Nanni P, Boschian Boschin R, Postorino M, Laureana R, Pasqualone G, Steffan A, Gentile M, Zucchetto A, Gattei V. Del Poeta G, et al. Among authors: gattei v. Hematol Oncol. 2021 Dec;39(5):712-714. doi: 10.1002/hon.2916. Epub 2021 Aug 30. Hematol Oncol. 2021. PMID: 34462939 Free PMC article. No abstract available.
267 results